Press Releases

Digital therapeutics deliver evidence-based treatment through software, and they are moving from niche apps into mainstream care as payers, regulators and clinicians gain confidence. According to IG Transformation Partners (IGTPS), the global digital therapeutics market was valued at USD 9.3 billion in 2025 and is projected to reach USD 48.0 billion by 2034, growing at a CAGR of 20.0% during 2026 to 2034. The complete digital therapeutics market report provides the full forecast, segmentation and company analysis.

This article covers the market’s definition, growth drivers, reimbursement developments, segment leaders, regional dynamics and competitive landscape.

What Is the Digital Therapeutics Market?

The digital therapeutics market covers evidence-based software interventions, delivered through applications, web platforms and connected devices, that prevent, manage or treat medical conditions such as diabetes, obesity, mental health disorders and respiratory disease.

IGTPS segments the market by application (diabetes, obesity, central nervous system disorders, cardiovascular diseases, respiratory diseases, others), component (software, hardware, services), sales channel (prescription-based, over-the-counter), end user (patients, healthcare providers, payers, employers) and region.

The market is shifting from standalone, single-condition mobile apps toward connected, multi-condition care platforms that combine software, sensors, coaching and prescribing in one workflow. Developers are also pairing digital treatment with drug therapy, including weight management programs built around anti-obesity medicines.

Market Size, Share and Forecast

IGTPS estimates the market at USD 9.3 billion in 2025 and USD 11.2 billion in 2026, rising to USD 48.0 billion by 2034, about five times the 2025 base.

Key Market Trends and Developments

Connected Multi-Condition Platforms

Developers are moving from single-condition apps to platforms covering diabetes, hypertension, weight, sleep and behavioral health within one member experience. This reduces the number of vendors that health plans and employers must manage and gives buyers a single data view of each member.

AI-Guided Personalization

Artificial intelligence adjusts lesson order, reminder timing and coaching prompts based on how each patient behaves in the application. Machine learning models flag members who are losing interest so care teams can step in early. These tools support program completion, which IGTPS identifies as the main clinical factor linked to digital therapeutic outcomes.

Pairing With Prescription Drugs

Drug makers are pairing digital treatment with prescription medicines to improve adherence and differentiate branded therapies. Combination programs for obesity, oncology, immunology and mental health are appearing in partnership deals.

New US Regulatory and Payment Pilots

The US FDA announced the TEMPO pilot alongside the CMS ACCESS model, whose first cohort began in July 2026. The FDA has since selected Dexcom as the first TEMPO participant. The pilot lets chosen digital health devices serve ACCESS participants while manufacturers collect real-world data to support later marketing authorization.

What Is Driving Digital Therapeutics Market Growth?

Chronic Disease Burden and Reimbursement

Diabetes, obesity, hypertension and mental health conditions are raising treatment demand faster than clinics can add staff. Digital programs extend care between visits without adding appointment capacity. Payers are shifting from paying only for drugs and procedures toward paying for software that produces measurable outcomes, and outcome-linked contracts reduce the financial risk of trying a new product.

Strengthening Clinical Evidence

Randomized controlled trials now support digital treatment for insomnia, depression, anxiety, migraine and substance use disorders. Because clinical guidelines already recommend cognitive behavioral therapy as first-line care for several of these conditions, software that delivers the same therapy fits into existing treatment pathways.

Government Reimbursement Pathways

Germany’s BfArM reported 251 applications to its DiGA fast-track procedure as of 15 July 2026, with 60 positive decisions, and around 73 million people covered by statutory health insurance are entitled to a prescribed DiGA. In the United States, Medicare payment codes for digital mental health treatment devices were extended to devices for attention-deficit hyperactivity disorder in the 2026 Medicare Physician Fee Schedule, and the Access to Prescription Digital Therapeutics Act introduced in 2025 proposes a dedicated Medicare benefit category.

Market Restraints and Challenges

IGTPS analysis points to several constraints.

• Fragmented reimbursement. Clinical claims, reimbursement routes and approvals differ by country and indication, so no single company holds a dominant global share.
• Evidence requirements. Randomized trial data and regulatory clearance are key success factors, which raises the cost and time of market entry.
• Engagement and completion. Clinical outcomes depend on program completion, so products that fail to keep patients engaged struggle to prove value.
• Prescribing workflow friction. Early prescription volumes were limited by workflow barriers, which electronic prescribing links and pharmacy-style code delivery are only now reducing.
• Policy dependence. Several US coverage developments are pilots or proposals, so timing and scope remain uncertain.

Market Opportunities and Future Outlook

Companion Programs for Obesity Medicines

Anti-obesity medicines create a large group of patients who need structured support on nutrition, muscle preservation and long-term habit change. Digital programs paired with these prescriptions can improve persistence on treatment, giving developers a clear clinical role and giving payers a way to protect the value of expensive drug spending. Omada Health will serve as an independent program administrator in Eli Lilly’s Employer Connect program, offering its GLP-1 Care Track directly to employers.

Neurology and Psychiatry

Attention deficit, psychosis, chronic pain and cognitive decline have few non-drug options, and pipeline products continue to enter pivotal studies. New approvals would open additional prescriber groups such as neurologists and psychiatrists.

Emerging Economies

Rising smartphone use and public digital health infrastructure in India, Brazil and Saudi Arabia support remote delivery of chronic care. Local language content and low-cost distribution through public health systems can reach large populations that lack easy access to specialists.

The outlook favors multi-condition platforms, reimbursed prescription products and companion programs linked to drug therapies.

Market Segmentation Analysis

To preview how these segments are presented in the report, readers can request the free sample pages.

By Application

Diabetes led in 2025 because the condition requires daily self-management, which software handles well through glucose tracking, dietary guidance, medication reminders and coaching. Central nervous system disorders are projected to grow fastest. Regulators have cleared prescription software for depression, generalized anxiety, insomnia, migraine and ADHD, and shortages of psychiatrists and therapists create an access gap that scalable digital cognitive behavioral therapy can address.

By Component

Software led because the core intervention in most products is delivered through applications and web platforms, which scale at low marginal cost and run on devices patients already own. Services are projected to grow fastest as buyers want human coaching, clinical oversight, onboarding and remote monitoring alongside software, and outcome-based contracts reward vendors that keep patients engaged.

By Sales Channel

Over-the-counter delivery led because most programs reach users through employers, health plans and direct-to-consumer subscriptions that do not require an individual prescription. Prescription-based delivery is projected to grow fastest as regulators create clearer pathways, payers build billing rules and physicians trust products backed by randomized trials.

By End User

Patients led because they are the direct users of every product and the point where engagement and outcomes are measured. Healthcare providers are projected to grow fastest as hospitals, specialty clinics and physician practices start to prescribe digital treatment as part of routine care plans. Payers and employers complete the segmentation.

Regional Analysis

North America leads through early FDA clearances for prescription software, expanding Medicare and commercial payer coverage and a large base of employer-sponsored digital care programs. Canada offers provincial virtual care programs that can host digital treatment, and Mexico’s large diabetes population supports early demand for remote chronic care.

Asia-Pacific is projected to grow fastest. Japan leads the region, with regulatory approval and national insurance coverage for prescription treatment apps, including products for hypertension and nicotine dependence. South Korea’s Ministry of Food and Drug Safety has approved locally developed digital therapeutic devices for insomnia. China combines a large population with diabetes and mental health needs, and India offers a fast-growing smartphone base and the Ayushman Bharat Digital Mission infrastructure.

Europe is anchored by Germany’s DiGA pathway, which shows how a national route turns regulatory approval into patient access. Latin America and the Middle East and Africa are also covered in the report.

Competitive Landscape and Key Companies

IGTPS describes the market as fragmented, with digital-first specialists, chronic care platforms and pharmaceutical partners competing across conditions and geographies. Click Therapeutics, Omada Health, Big Health, DarioHealth and Welldoc compete on clinical evidence, payer contracts and platform breadth. Other profiled players include Hinge Health, Sword Health, Sidekick Health, Oviva, HelloBetter, Selfapy, CureApp, Luminopia, Freespira and Lumos Labs.

Recent developments cited by IGTPS:

• January 2026: Sword Health acquired Kaia Health in a deal valued at USD 285 million, adding musculoskeletal and pulmonary programs and a position in Germany’s DiGA pathway.
• February 2026: Big Health raised USD 23.7 million to expand adoption of SleepioRx and DaylightRx.
• February 2026: Freespira launched its fifth-generation sensor device for panic disorder and PTSD.
• April 2026: Boehringer Ingelheim invested USD 50 million in Click Therapeutics’ Series D and transferred full commercial rights for CT-155, an investigational prescription digital therapeutic for negative symptoms of schizophrenia.

Strategic Implications for Industry Participants

Developers should invest in randomized trial evidence and regulatory clearance, and design multi-condition platforms that reduce vendor counts for payers and employers.

Pharmaceutical companies can use companion digital programs to support adherence and differentiate branded therapies, as the Boehringer Ingelheim and Click Therapeutics agreement illustrates.

Payers and employers should favor outcome-linked contracts that tie payment to measurable results and engagement.

Investors should watch consolidation, as larger platforms acquire smaller developers to add regulated products and reimbursement access in markets such as Germany and Japan.

Why Choose IG Transformation Partners

IG Transformation Partners is a market research and industry intelligence provider serving life science, ICT, consumer products and other industries. This report offers 170 to 180 pages and 55 to 65 market tables, delivered as a PDF report with a data sheet and analyst support. IGTPS also offers customized research and consulting services. Its published strengths include strong industry focus, comprehensive reports, value chain analysis, growth dynamics, quality assurance and regular report updates.

Conclusion

The digital therapeutics market is projected to grow from USD 9.3 billion in 2025 to USD 48.0 billion by 2034 at a 20.0% CAGR. Chronic disease burden, stronger clinical evidence and expanding reimbursement are driving growth, while obesity companion programs, neurology and emerging markets offer new opportunities. Companies that combine trial-backed products, regulatory clearance and payer-ready outcome reporting will be best positioned in a fragmented, fast-evolving market.

Frequently Asked Questions

What is the digital therapeutics market?

It covers evidence-based software interventions, delivered through applications, web platforms and connected devices, that prevent, manage or treat medical conditions such as diabetes, obesity, mental health disorders and respiratory disease. Products may be prescribed or accessed through employers, health plans or direct-to-consumer channels.

How big is the digital therapeutics market?

IGTPS values the market at USD 9.3 billion in 2025 and USD 11.2 billion in 2026. It is projected to reach USD 48.0 billion by 2034, driven by chronic disease burden, clinician acceptance and expanding reimbursement.

What is the CAGR of the digital therapeutics market?

IGTPS projects a CAGR of 20.0% for 2026 to 2034. Growth reflects the shift from single-condition apps to multi-condition platforms, the creation of reimbursement pathways and rising demand for scalable chronic care.

What is the forecast for digital therapeutics through 2034?

The market is forecast to grow from USD 9.3 billion in 2025 to USD 48.0 billion by 2034. IGTPS expects prescription-based products, companion programs for obesity medicines and expansion in Asia-Pacific to contribute to growth.

What are the key trends in digital therapeutics?

Key trends include connected multi-condition platforms, AI-guided personalization, pairing digital treatment with prescription drugs, and new US pilots such as the FDA TEMPO pilot linked to the CMS ACCESS model, whose first cohort began in July 2026.

What is driving growth in the digital therapeutics market?

The main drivers are rising chronic disease burden and expanding reimbursement. Randomized trials supporting digital treatment for conditions such as insomnia, depression and anxiety are also strengthening physician trust, and Germany’s DiGA pathway shows how reimbursement turns approval into access.

Which application and sales channel lead the market?

Diabetes held the largest application share in 2025, and over-the-counter delivery held the largest sales channel share. Central nervous system disorders and prescription-based delivery are projected to grow at the fastest CAGR in their segments.

Which region dominates the digital therapeutics market?

North America held the largest share in 2025 at about 40%, supported by early FDA clearances, payer coverage and employer programs. Europe held about 28%, and Asia-Pacific is projected to grow fastest, led by Japan, South Korea, China and India.

Who are the key companies in digital therapeutics?

IGTPS profiles Click Therapeutics, Omada Health, Big Health, DarioHealth, Welldoc, Hinge Health, Sword Health, Sidekick Health, Oviva, HelloBetter, Selfapy, CureApp, Luminopia, Freespira and Lumos Labs. The market is fragmented, with no single company holding a dominant global share.

What are the main challenges for digital therapeutics?

Challenges include reimbursement that differs by country and indication, the need for randomized trial evidence and regulatory clearance, patient engagement and completion, prescribing workflow friction and uncertainty around evolving US policy. Vendors with strong evidence and payer contracts are better positioned.

Get the Full Digital Therapeutics Market Report

Access forecasts to 2034, segmentation by application, component, sales channel and end user, regional and country analysis, company profiles and recent developments. Use the data to guide investment, product and partnership decisions.

Access the Full Market Report

https://www.igtps.com/report/digital-therapeutics-market

Review the Report Before You Buy

Request the sample pages to preview the report’s structure, tables and analysis, and confirm it matches your research needs.

Download Free Sample Pages

https://www.igtps.com/download-free-sample/digital-therapeutics-market?P=03

Related IGTPS Reports

Virtual Healthcare Market
Relevant for readers following remote care delivery and outcome-based chronic disease programs.
Explore the Full Report
https://www.igtps.com/report/virtual-healthcare-market

AI-Powered Clinical Documentation Market
Relevant for readers tracking AI adoption and regulatory guidance in healthcare IT.
Explore the Full Report
https://www.igtps.com/report/ai-powered-clinical-documentation-market

AI Medical Imaging Software Market
Relevant for readers comparing software-based clinical products and FDA pathways.
Explore the Full Report
https://www.igtps.com/report/ai-medical-imaging-software-market